Drug Type Fusion protein |
Synonyms |
Target |
Mechanism IL2RA inhibitors(Interleukin-2 receptor alpha chain inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | 23 Sep 2024 | |
Melanoma | Phase 2 | US | 23 Sep 2024 | |
Renal Cell Carcinoma | Phase 2 | US | 23 Sep 2024 |